Remdesivir News and Research

RSS

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the study findings, which are yet to be peer-reviewed, the scientists recommend that for effective inhibition of SARS-CoV-2 infection, remdesivir should be used with other antiviral medicines, or its dosing regimen should be optimized to improve bioavailability.

22 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

A new study, released as a preprint on bioRxiv* server, shows that a combination of the biological interferon-α and the small molecule nafamostat are effective against SARS-CoV-2 infection in vitro, as well as in vivo.

18 Jun 2021

Researchers prepare for next coronavirus pandemic

Scientists are already preparing for a possible next coronavirus pandemic to strike, keeping with the seven-year pattern since 2004.

17 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Researchers develop new imaging technique for studying nanoscale coronavirus-host interactions

Lei S. Qi of Stanford University, California, and colleagues published research showing a potential framework to better characterize coronaviruses' biology. While most high-resolution imaging techniques show the life cycle of coronaviruses, identifying viral or host proteins and genomes remains poorly understood. Their results use multi-color super-resolution imaging allows them to study nanoscopic parts of the coronavirus, including RNA.

14 Jun 2021

Eldelumab and Fenofibrate show potential for COVID-19

In a new study posted to the medRxiv* preprint server, researchers from the University of Pittsburgh and Barrow Neurological Institute report the results of their analysis of several RNA-Seq studies and used computational approaches to discover potential drugs against COVID-19.

10 Jun 2021

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

The report, published in the journal Clinical Infectious Diseases, revealed that the variant detected has been spreading at an alarming rate since November. By February 2021, it accounted for 12.3 percent of all cases in the area.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

Using AI to fight COVID-19

A study based in Taiwan and published in the Journal of Clinical Medicine focuses on the role of AI in managing COVID-19 through digital images, clinical and laboratory analysis such as screening and diagnosis.

7 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

Scientists identify many existing drugs with antiviral activity against coronavirus

Mining the world's most comprehensive drug repurposing collection for COVID-19 therapies, scientists have identified 90 existing drugs or drug candidates with antiviral activity against the coronavirus that's driving the ongoing global pandemic.

3 Jun 2021

Known pharmaceutical compounds could provide new therapies for COVID-19

After screening over 12,000 existing treatments, researchers have found many promising antiviral compounds that could treat COVID-19.

3 Jun 2021

Long COVID patients at higher risk of small airway disease

The preprint discussed herein describes the effects of SARS-CoV-2 on lung structure and function in patients with long COVID.

2 Jun 2021

ALG-097111 potently inhibits SARS-CoV-2 replication in Syrian Hamster model in vivo

A team of researchers from the US and Belgium applied a structure-based approach with early monitoring of cathepsin L inhibition along with SARS-CoV-2 3CLpro inhibition. They identified a potent and selective SARS-CoV-2 3CLpro inhibitor, ALG-097111, which has proven activity against SARS-CoV-2 in SARS-CoV-2 hamster models in vivo. This study is published in the journal, Biochemical and Biophysical Research Communications.

1 Jun 2021

Study links barotrauma to COVID-19 in younger patients

To better understand the possible relationship between severe infection and poor in-hospital outcomes, researchers from the Internal Medicine, and the Pulmonary Critical Care Medicine, Rutgers University, Newark, USA, presented a case series linking barotrauma to COVID-19 in younger patients.

28 May 2021

New favipiravir derivative is a potent SARS-CoV-2 inhibitor

In a new study recently published in Chemical Papers by Dr. Amgad Rabie (May 16th, 2021), a high potency derivative of favipiravir towards SARS-CoV-2 is engineered and investigated.

27 May 2021